Abstract
It has been reported that myocardial mitochondrial function can be improved by the administration of co-enzyme Q10 (CoQ10). Recently, iodine-123 labelled 15-(p-iodophenyl)-3-(R, S)-methylpentadecanoic acid (BMIPP) was developed for metabolic imaging using single-photon emission tomography (SPET). This study was conducted to determine whether the therapeutic effects of CoQ10 on idiopathic dilated cardiomyopathy can be evaluated by BMIPP myocardial SPET. Fifteen patients, comprising 14 men and one woman (mean age: 64±12 years), were examined. CoQ10 was administered at 30 mg/day for a period of 35.7±12.4 days. BMIPP myocardial SPET was carried out belote and after CoQ 10 treatment. The count ratio of the heart (H) to the upper mediastinum (M) (H/M ratio) was calculated using a region of interest method with anterior planar imaging. Representative short-axis tomograms were divided into 27 segments (three slicesxnine segments). Each segmental score was analysed semiquantitatively using a four-point scoring system (normal=0, mild low uptake=1, severe low uptake=2, defect=3). The H/M ratio showed a significant improvement., from 2.39±0.39 to 2.54±0.47, after treatment (P<0.05). The BMIPP total defect score after CoQ10 treatment was significantly decreased to 10.1±43, compared to 13.9±4.5 without CoQ10 treatment (P<0.001). However, the percent fractional shortening measured using echocardiography was not significantly different before and alter CoQ treatment (19.2±8.1 vs 19.7±7.1). BMIPP myocardial SPET was confirmed to be sensitive in evaluating the therapeutic effects of CoQ 10 in patients with idiopathic dilated cardiomyopathy. This method is unique, since the therapeutic effects can be estimated from the perspective of metabolic SPET imaging.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Yamamichi Y, Kusuoka H, Morishita K, Shirakami Y, Kurami M, Okano K, Itoh O, Nishimura T. Metabolism of iodine-123-BMIPP in perfused rat heart.J Nucl Med 1995; 36: 1043–1050.
Knapp FF, Kropp J. Iodine-123-labelled fatty acids for myocardial single-photon emission tomography: current status and future perspectives.Eur J Nucl Med 1995; 22: 361–381.
Fujibayashi Y, Yonekura T, Takemura Y, Wada K, Matsumoto K, Tamaki N, Konishi J, Yokoyama A. Myocardial accumulation of iodinated beta-methyl-branched fatty acid analogue, iodine-125-15-(p-iodophenyl)-3-(R,S)-methylpentadecanoic acid (BMIPP) in relation to ATP concentration.J Nucl Med 1990: 31: 1818–1822.
Ogata M, Myocardial uptake of125I-BMIPP in rats treated with adriamycin.Jpn J Nucl Med 1989; 26: 69–76.
Torizuka K, Yonekura Y, Nishimura T, Tamaki N, Uehara T. Phase 2 study of β-methyl-p-(123I)-iodophenyl-pentadecanoic acid, a myocardial imaging agent for evaluating myocardial fatty acid metabolism.Jpn J Nucl Med 1992; 29: 305–317.
Torizuka K, Yonekura Y, Nishimura T, Ohtake T, Bungo H, Tamaki N, Yehara T. Phase 3 study of β-methyl-p-(123I)-iodophenyl-pentadecanoic acid, a myocardial imaging agent for evaluating myocardial fatty acid metabolism—A multi-center trial.Jpn J Nucl Med 1992; 29: 413–433.
Hatefi Y, Haavik AG, Griffiths DE. Reconstitution of the electron transport.Biochem Biophys Res Commun 1961; 4: 447–453.
Azuma j, Sawamura A, Awata N. Usefulness of Taurin in chronic congestive heart failure and its prospective application.Jpn Circ J 1992; 95–99.
Folkers K, Littarru GP, Runge TM, Havanonda S, Colley D. Evidence for a deficiency of coenzyme Q10 in human heart disease.Int J Vitam Nutr Res 1970; 40: 380–390.
Dohmae M, Sawada H, Tashima M, Uchino H, Matsuyama E, Konishi T. Chronic toxicites adriamycin (ADR) and their possible prevention by coenzyme Q10.J Jpn Soc Cancer Ther 1979; 14: 1009–1028.
Nagai S, Miyazaki Y, Ogawa K, Satake T, Sugiyama S, Ozawa T. The effect of coenzyme Q10 on reperfusion injury in canine myocardium.J Mol Cell Cardiol 1985; 17: 873–894.
Ogasawara S, Nishikawa Y, Yorifuji S, Soga T, Nakamura Y, Takahashi M, Tarui K. Treatment of Kearn-Sayre syndrome with coenzyme Q10.Neurology 1986, 36: 45–53.
Langsjoen P, Vadhanavikit S, Folkers K. Response of patients in classes II and IV of cardiomyopathy to therapy in a blind and crossovers trial with coenzyme Q10.Proc Natl Acad Sci USA 1985; 82: 4240–4244.
Ichihara T, Ogawa K, Motomura N, Kubo A, Hashimoto S. Computer scatter compensation using the triple energy window method for single and dual isotope SEPCT.J Nucl Med 1993; 34: 2216–2221.
Hashimoto A, Nakata T, Tsuchihashi K, Tanaka S, Fujimori K, Iimura O. Postischemic functional recovery and BMIPP uptake after primary percutaneous transluminal coronary angioplasty in acute myocardial infarction.Am J Cardiol 1996; 77: 25–30.
Tamaki N, Kawamoto M, Yonekura Y, Fujibayashi Y, Takahashi N, Konishi J, Nohara K, Kambara H, Kawai C, Ikekubo K, Kato H. Regional metabolic abnormality in relative to perfusio and wall motion in patients with myocardial infarction: assessment with emission tomography using an iodinated branched fatty acid analog.J Nucl Med 1992; 33: 659–667.
Nishimura T, Uehara T, Shimonagata T, Nagata S, Haze K. Clinieal experience of123I-BMIPP myocardial imaging for myocardial infarction and hypertrophie cardiomyopathy.Ann Nucl Med 1993; 7: SII–35-SI–39
Kurata C, Kobayashi A, Yamazaki N. Dual tracer autoradiographic study with thallium-201 and radioiodinated fatty acid in cardiomyopathie hamsters.J Nucl Med 1989; 30: 80–87.
Barrie SE, Saad EA, Lacaz P, Da Sira, Harris P. Myocardial enzyme activites in congestive cardiomyopathy.Res Commun Chem Pathol Pharmacol 1979; 23: 375–381.
Folkers K, Vadhanavikit S, Mortensen SA. Biochemical rationale and myocardial tissue data on the effective therapy of cardiomyopathy with coenzyme Q10.Proc Natl Acad Sci USA 1985; 82: 901–904.
Kadowaki T, Kadowaki H, Mori T, Tobe K, Sakuta R, Sasaki Y, Tanabe Y, Sakura H, Awata T, Goto Y, Akanuma Y, Yazaki Y. A subtype of diabetes mellitus associated with a mutation in the mitochondrial gene.N Engl J Med 1994; 330: 962–968.
Suzuki Y, Moriyama Y, Atsumi Y, Katagiri H, Kadowaki T, Oka Y, Hosokawa K, Kimura M, Matsuoka K. A case of mitochondrial diabetes mellitus with various autonomic symptoms and subclinical cardiac dysfunction.J Jpn Diab Soc 1995; 38: 39–44.
Lenaz G, Daves GD, Folkers K. Organic structural specificity and sites of coenzyme Q10 in succinoxidase and DPNH-oxidase systems.Arch Biochem Biophys 1968; 123: 539–550.
Choe JY, Combs AB, Saji S, Folkers K. Study of the combined and separate administration of doxorubicin and coenzyme Q10 on monse cardiac enzymes.Res Commun Chem Pathol Pharmacol 1979; 24: 595–598.
Langsjoen PH, Folkers K. Long-term efficacy and safety of coenzyme Q10 therapy for idiopathic dilated cardiomyopathy.Am J Cardiol 1990; 65: 521–523.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kim, Yi., Sawada, Y., Fujiwara, G. et al. Therapeutic effect of co-enzyme Q10 on idiopathic dilated cardiomyopathy: assessment by iodine-123 labelled 15-(p-iodophenyl)-3(R, S)-methylpentadecanoic acid myocardial single-photon mission tomography. Eur J Nucl Med 24, 629–634 (1997). https://doi.org/10.1007/BF00841400
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00841400